Olmesartan/Hydrochlorothiazide Clonmel (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan/Hydrochlorothiazide Clonmel is prescribed for cardiovascular conditions that require blood‑pressure reduction.

• Hypertension: Improves blood‑pressure control when monotherapy is insufficient.
• Hypertensive heart disease: Reduces cardiac workload and risk of progression.
• Chronic kidney disease with hypertension: Helps slow renal function decline associated with high blood pressure.

• Olmesartan medoxil blocks the angiotensin II type 1 (AT1) receptor, preventing vasoconstriction and aldosterone release, while hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, increasing urinary water excretion. The combined actions decrease systemic vascular resistance and plasma volume, producing an overall antihypertensive effect.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Fatigue
• Increased urination
• Electrolyte disturbances (e.g., low potassium)
• Mild gastrointestinal upset

Serious or Rare Side Effects

• Severe hypotension
• Acute kidney injury
• Hyperkalemia or severe electrolyte imbalance
• Angio‑edema
• Liver function abnormalities
• Blood dyscrasias such as agranulocytosis

Before starting Olmesartan/Hydrochlorothiazide Clonmel, consider the following safety measures:

• Renal function: Assess baseline kidney function and monitor periodically.
• Electrolytes: Check serum potassium and sodium levels, especially in patients on other diuretics.
• Blood pressure: Monitor for excessive drops, particularly after the first dose.
• Pregnancy: Avoid use during pregnancy due to potential fetal risk.
• Drug allergies: Discontinue if signs of angio‑edema or hypersensitivity develop.
• Store at ambient temperature: Keep below 25°C in the original packaging, protected from moisture.

Olmesartan/Hydrochlorothiazide Clonmel can interact with several medicines; clinicians should review patient medication lists.

Major Interactions (Avoid)

• Aliskiren (in diabetic patients): Increases risk of renal impairment and hyperkalemia.
• Potassium‑sparing diuretics or supplements: May cause dangerous hyperkalemia.
• NSAIDs (e.g., ibuprofen, naproxen): Can blunt antihypertensive effect and worsen kidney function.

Moderate Interactions (Monitor Closely)

• Lithium: May increase lithium levels, risking toxicity.
• Antidiabetic drugs: May enhance glucose‑lowering effect, requiring dose adjustment.
• Other antihypertensives: May cause additive blood‑pressure lowering.
• CYP450 inhibitors: May modestly raise olmesartan concentrations.
• High‑dose corticosteroids: May counteract diuretic effect and affect electrolytes.